Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

This study is evaluating the safety of Prismocitrate 18 — a citrate-based solution used to prevent blood from clotting in tubes during continuous kidney replacement therapy (CRRT), a form of dialysis used in critically ill patients. It is designed for patients who cannot take heparin (a standard blood thinner). You may be eligible if: - You are 18 or older - You are a candidate for CRRT (continuous renal replacement therapy) - You have a contraindication to heparin or an increased risk of bleeding - You are expected to survive for at least 24 hours - You or your legal representative can provide written informed consent You may NOT be eligible if: - You have a known allergy to citrate or a history of citrate toxicity - You have acute liver failure or acute-on-chronic liver failure (Child-Pugh score above 10) - You have refractory shock with severe lactic acidosis (lactate above 4 mmol/L) - Your blood calcium level is outside the normal range and cannot be corrected - You are pregnant or breastfeeding - You are currently enrolled in another interventional clinical study Talk to your doctor to see if this trial is right for you.